New Era of Leadership: Spotlight on Dr. L H Hiranandani Hospital CEO
The healthcare industry is rapidly evolving, and at the heart of this transformation are visionary leaders who are driving institutions toward innovation, patient-centricity, and clinical excellence. One such leader making a significant impact is the Dr. L H Hiranandani Hospital CEO, who has ushered in a new era of strategic leadership and progressive medical care.In this blog, we delve into how the Dr. L H Hiranandani Hospital CEO is not just maintaining the hospital's legacy but actively redefining its future, prioritizing innovation, human compassion, and excellence in every sphere of healthcare delivery.
Key Milestones in Progress Toward Patient Centricity
by Kim McCleary, Acting Executive Director, Managing Director
In 2012, digital strategist Leonard Kish declared, “If patient engagement were a drug, it would be the blockbuster drug of the century and malpractice not to use it,” a line seized by patient advocates and media alike to mark a new dawn in the patient-centricity movement. The advancements made that year through policy initiatives, collaborative efforts, and foundation-led programs opened the floodgates for the rush of activity that we are seeing in the patient-centricity movement today.
Our recent publication, From Aspiration to Application: 5 Years of Patient Centricity, provides stories of impact and milestones from the ongoing movement. This expanded timeline guides you through the events that laid the foundation for where we are today.
2012:
• The Food and Drug Administration Safety and Innovation Act (FDASIA) passes (including Prescription Drug User Fee Act [PDUFA]-V), which requires the Patient-Focused Drug Development initiative and structured benefit-risk assessment that incorporates patient perspectives.
• The Patient-Centered Outcomes Research Institute’s (PCORI) “Year of Engagement” establishes priorities and initiates funding for comparative effectiveness research that meaningfully incorporates patient perspectives on outcomes that matter to them.
• The Institute of Medicine assesses the National Institutes of Health’s (NIH) Clinical and Translational Science Award program and reinforces the “value of community engagement to shortening the time between discovery and application, and to improve the uptake of research findings by the public.
• The European Union’s Innovative Medicines Initiative commences support for an academy on therapeutic innovation to empower patients to work with regulators, health-care professionals, and industry to influence medicines development for patient benefit.
2013:
• Health Affairs dedicates its February issue to the growing body of evidence that when patients are involved in their health and health care, they tend to have better outcomes at lower cost.
• The Clinical Trials Transformation Initiative (CTTI), a consortium of life sciences companies, FDA, and patient organizations, establishes a Patient Groups and Clinical Trials project to develop models for better engaging patients as partners in clinical trials. It later popularizes a chevron diagram illustrating opportunities to engage patients across the full continuum of research.
• FDA’s Center for Drug Evaluation and Research hosts first of 24 Patient-Focused Drug Development meetings, each of which results in a detailed “Voice of the Patient” report.
• FDA’s Center for Devices and Radiological Health (CDRH) launches the Patient Preference Initiative with a two-day workshop to explore ways to better incorporate patient perspectives into its regulatory decisions.
2014:
• PCORI invests $250 million to create the National Patient-Centered Clinical Research Network (PCORnet), composed of Patient-Powered Research Networks and Clinical Data Research Networks, to support research that is faster, easier, less costly, and more relevant to making informed health-care decisions.
• National Health Council issues a stratification tool and guide to help patient organizations collect information about their communities that may be helpful to FDA in making benefit-risk assessments. This tool is one of the first created in response to opportunities enacted in FDASIA for more integration of patient perspectives.
• FasterCures convenes a “Benefit-Risk Boot Camp” to educate life sciences professionals, academics, and patient organizations about opportunities for patient perspectives to inform regulatory decisions about benefit-risk tradeoffs.
• Parent Project Muscular Dystrophy (PPMD) enlists more than 80 community members and stakeholders to draft the first-ever regulatory guidance submitted by a patient advocacy organization with the goal of accelerating development and regulatory review of applications for new medicines to treat Duchenne muscular dystrophy. The FDA issues formal guidance a year later, drawing heavily on PPMD’s draft.
2015:
• In his State of the Union address, President Obama outlines a new Precision Medicine Initiative to “empower patients, researchers, and provider to work together toward development of individualized care.”
• FDA approves the Maestro Rechargeable System for treatment of obesity, notable because the clinical study did not fully meet its primary endpoints but the device performed in line with patients’ stated preferences for benefit-risk tradeoffs.
• Medical Device Innovation Consortium issues a framework for integrating patient perspectives in the total product life cycle of medical devices, along with a catalog of methods for assessing patient preferences.
• CTTI publishes recommendations for effectively engaging patients in the development and conduct of clinical trials.
• CDER issues guidelines for FDA participation in externally led Patient-Focused Drug Development meetings to expand impact beyond 24 conditions selected under PDUFA-V.
2016:
• European Union Patient Academy for Therapeutic Innovation (EUPATI) releases the “Toolbox on Medicines R&D” in seven languages, attracting more than 110,000 visitors within the first year.
• CDRH names partnering with patients as one of three strategic priorities for 2016-2017 and issues final guidance on how FDA may consider patient preference information in the assessment of the benefit-risk profile of certain medical devices.
• 21st Century Cures Act (P.L. 114-255) passes the Senate on Dec. 7, 2016, and is signed into law on Dec. 13, expanding opportunities for patient input to be factored into regulatory decisions.
2017:
• Reauthorization of PDUFA and the Medical Drug User Fee Amendments (MDUFA) contain key provisions to enhance the science of patient input.
• FDA proposes the creation of a central Office of Patient Affairs to be housed within the Office of the Commissioner.
• FasterCures and Avalere release version 1.0 of the Patient Perspective Value Framework and methodology designed to assess the patient perspective on the value of medical products and health-care services.
• The People-Centered Research Foundation is launched to provide long-term sustainability for PCORnet and to pioneer novel methods for generating evidence that leads to better care and patient health.
• NIH launches the beta phase of the “All of Us” cohort of the Precision Medicine Initiative, enrolling the first group of individuals who will form the million-person research community of citizen scientists and academic researchers.
• The Food and Drug Administration Reauthorization Act, including PDUFA and MDUFA provisions enhancing the science of patient input, is signed into law on Aug. 18, 2017.
• FDA convenes the Patient Engagement Advisory Committee, the first committee dedicated to helping the agency increase integration of patient perspectives into regulatory decision-making.
Through FasterCures' work in our Patients Count program, we will strive to build on these accomplishments and foster patient-centric policies and practices that enable greater patient participation in decision-making.
Surprise! EHR's are hurting not helping the doctor /patient relationship.
Surprise! EHR’s are hurting not helping the doctor /patient relationship.
Summary: A healthy Patient-Doctor relationship is the core of all healthcare. This reports on a JAMA* study as well as one brilliant doctors’ personal view on the impact of EHR’s on that hallowed relationship.
When JAMApublishes a study, everyone pays attention. But this was not a clinical study; this was research into the impact of EHR’s (Electronic Health Records) on the patient-doctor…
